End of funding period

Angiotensin Converting Enzyme (ACE) inhibitors are among the most important and widely prescribed drugs. They reduce the morbidity and mortality associated with high blood pressure, heart disease, and kidney disease. Unfortunately, their use carries the risk of causing life-threatening airway swelling in some patients. There is currently no treatment for this condition. A novel treatment approach that may reduce or completely reverse the swelling will be tested.

The investigators will test the hypothesis that treatment with fresh frozen plasma that contains high levels of ACE activity will increase serum ACE activity and thereby cause the degradation of mediators of ACE inhibitor-induced angioedema, such as bradykinin and substance P, resulting in a shortening of the course of ACE inhibitor-induced angioedema.

16 patients with ACE inhibitor-induced angioedema will be randomized 1:1 to treatment with either 2 units of fresh frozen plasma that has been preselected for high ACE activity content (≥50 U/L) or an equal volume of normal saline. A baseline assessment of the severity of the angioedema will be performed and baseline serum levels of ACE activity will be determined. The severity of angioedema will be assessed and serum levels of ACE activity will be determined at specific intervals after each subject is treated.

Inclusion Criteria:

• Males and females 18 years of age or older
• Must currently be on ACE inhibitor therapy and have received a dose within 36 hours
• Presenting with moderate to severe angioedema affecting the upper aerodigestive tract (face, lips, cheeks, tongue, soft palate/uvula, pharynx, and larynx). The severity of the angioedema attack will be determined by the subject's worst severity rating at baseline among 4 clinical domains (difficulty breathing, difficulty swallowing, voice changes, and tongue swelling) based on a clinically validated angioedema severity scale29 (Table)
• Presenting with ACE inhibitor-induced angioedema within 12 hours after onset
• All females must have a locally obtained negative pregnancy test prior to administration of the study drug. Those who have had a total hysterectomy, bilateral oophorectomy, or are two years post-menopausal do not require a pregnancy test.
• Must be able to provide written informed consent to participate in the study to fulfill all study requirements

Exclusion Criteria:

• Pregnancy and/or breast feeding
• Patients with angioedema that is likely due to causes other than ACE inhibitors, including hereditary angioedema, acquired angioedema, and allergic angioedema (food, insect bite or sting with clear response to anti-allergy medications)
• Patients exhibiting acute urticaria
• Evident clinical response to glucocorticoids, antihistamines, or epinephrine
• A family history of recurrent angioedema
• Documented intolerance to plasma
• Documented congenital deficiency of immunoglobulin A in the presence of anti-immunoglobulin A antibodies
• Patients with heart failure of the severity that precludes safe transfusion of High ACE activity plasma
• Patients with acute pulmonary edema
• Patients with morbid obesity as defined by BMI>40; morbidly obese patients have a higher volume of blood needing higher amounts of plasma and therefore will be excluded from this pilot study
• Opinion of the investigator that the patient would not be a good candidate
• Participation in a clinical study in the past 30 days

No patients were randomized to the High ACE FFP. Study was terminated due to end of funding period.

Patients were observed for adverse effects during their ED visit only, or up to 24 hours. No further monitoring was conducted after the patient was discharged from the ED. Both participants received placebo (normal saline).

Both enrolled participant were randomized to the placebo arm, which they recieved normal saline..

The laboratory that performs the assays and the assessor of the angioedema will be blinded to the treatment the subject received.